SAN RAFAEL, Calif.--(BUSINESS WIRE)--Eastbourne Capital Management, L.L.C. (“Eastbourne”) announced today that it has filed preliminary proxy materials with the Securities and Exchange Commission in connection with its solicitation of proxies in support of the election of its five proposed nominees to the 12 member Board of Directors of Amylin Pharmaceuticals, Inc. (“Amylin”) (NASDAQ: AMLN) at the Company’s 2009 Annual Meeting of Shareholders. The proposed nominees are Dr. Kathleen Behrens, Marina Bozilenko, Charles Fleischman, William Nuerge and Jay Sherwood. Eastbourne currently owns approximately 12.5% of Amylin’s outstanding shares. Eastbourne also announced that it today delivered a letter to the Board of Directors of Amylin, the full text of which is as follows:
